Navigation Links
Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
Date:6/24/2013

THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, delivered two oral and two poster presentations on LX4211 at the 73rd Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013.

Pablo Lapuerta, M.D., Lexicon's executive vice president, clinical development and chief medical officer, delivered an oral presentation titled "LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, Reduces Blood Pressure in Patients with Type 2 Diabetes."  This presentation highlighted the reductions in blood pressure by LX4211 for subgroups with varying blood pressures at baseline in a 12-week dose-ranging Phase 2b study of 299 patients with type 2 diabetes. Patients with high baseline systolic blood pressure (>130 mmHg) dosed with LX4211 experienced an average of 14 mmHg reduction in systolic blood pressure when compared to placebo (p=0.002). In contrast, patients with normal systolic blood pressure at baseline (<130 mmHg) experienced an average of 1 mmHg reduction (p=0.6). Systolic blood pressure readings below 100 mmHg, as well as orthostatic systolic blood pressure changes (changes due to a shift in position such as seated-to-standing and supine-to-standing), were no different between patients treated with LX4211 and those on placebo.

"This new analysis of data from the trial shows that LX4211 lowers blood pressure to a greater extent in those patients who are in the greatest need of treatment, that is, those patients with hypertension," said Dr. Lapuerta. "Furthermore, patients with normal blood pressure showed little or no change on LX4211
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
2. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
3. Lexicon To Present At The Jefferies Global Healthcare Conference
4. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
6. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
7. Lexicon to Report First Quarter Financial Results on May 10, 2013
8. Lexicon To Present At The Needham Healthcare Conference
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
10. Lexicon To Present At The BIO CEO & Investor Conference
11. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
(Date:3/29/2015)... 29, 2015 At this initial ... provides basic health information around medical conditions that ... these challenges as well as helping them find ... six medical conditions using evidenced based information in ... in conversations around them., , ...
(Date:3/29/2015)... North American Seminars receives Texas Board Physical Therapy ... . , Utilizing Pilates to Enhance Rehab ... # 56399TX      , The Interactive Shoulder Algorithm ... 10.5 hours - Texas Board of Physical Therapy      ... the SI Joint - 10 hours - Texas Board ...
(Date:3/28/2015)... March 28, 2015 Coffee could not only ... protect you from gum disease, researchers have found. , They ... disease. , Coffee contains antioxidants. Antioxidants fight gum disease. Does ... researchers at Boston Univ. Henry M. Goldman School of Dental ... August 2014 issue of the Journal of Periodontology. , “This ...
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
Breaking Medicine News(10 mins):Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2
... MORRISVILLE, Pa., Feb. 13 As the FDA ... risk evaluation and mitigation plans for extended release ... chronic pain have already discovered a resource that ... treatments. Emerging Solutions in Pain ( ...
... do more to promote awareness, study says , , FRIDAY, Feb. ... by name or role -- the doctors assigned to their ... , "The majority of hospitalized patients we looked at were ... said study author Dr. Vineet Arora, associate program director at ...
... national survey conducted by the Harvard Opinion Research Program at ... majority (93%) of Americans have heard or read about the ... aware of the recall, about six in ten (61%) say ... risk of getting sick from contaminated peanut products. Specifically, about ...
... YORK, Feb. 13 In a bid to help ... online auction of the Ysio Digital Radiology System, donated ... at $99,999 and jumped to a quarter million dollars ... Siemens (NYSE: SI ) at: , ...
... are under way , , FRIDAY, Feb. 13 (HealthDay ... Chinese medicine may be able to control allergic reactions ... City,s Mount Sinai School of Medicine report. , Food ... allergies among children have increased 18 percent since 1997, ...
... Corporation (Nasdaq: DYNT ) today announced results for ... 2008. Operating results showed significant improvement over the three and ... quarter ended December 31, 2008, improved to $89,917, compared to ... the prior fiscal year. Net income for the quarter ended ...
Cached Medicine News:Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 2Health News:Opioid Safety and Efficacy Web Resource for Clinicians Supports Education and Practice Needs 3Health News:Many Hospital Patients Can't ID Their Doctors 2Health News:Many Hospital Patients Can't ID Their Doctors 3Health News:Following peanut product recall, six in ten Americans taking steps to reduce risk of sickness 2Health News:Following peanut product recall, six in ten Americans taking steps to reduce risk of sickness 3Health News:Herbal Remedy Could Halt Peanut Allergy 2Health News:Herbal Remedy Could Halt Peanut Allergy 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4
... These modified battery ... power supplies for GENIE ... to produce very specific ... reproducibility than laboratory power ...
... These modified battery chargers ... supplies for GENIE blotters. ... produce very specific voltages, ... than laboratory power supplies. ...
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
Inquire...
Medicine Products: